FDA Approves Frontline Cabozantinib for Advanced RCC

December 19, 2017 – The FDA has approved cabozantinib for previously untreated patients with advanced renal cell carcinoma (RCC), based on a meaningful improvement in progression-free survival (PFS) versus sunitinib in the CABOSUN trial. In the phase II study, first-line treatment with cabozantinib reduced the risk of progression or death by 52% compared with sunitinib for patients with advanced RCC. The median PFS was 8.6 months with cabozantinib versus … (leggi tutto)